Table 2.

Timing of B-cell maturation antigen (BCMA)-targeting treatment

Treatments	Total cilta-cel N = 18∗
	Responders n = 12	Nonresponders n = 6
Duration of last anti-BCMA treatment, days
Median	29.5	63.5
Range	1-277	22-527
Time from last anti-BCMA treatment to apheresis, days
Median	161.0	56.5
Range	26-695	40-895
Time from last anti-BCMA treatment and cilta-cel infusion, days
Median	235.0	117.5
Range	62-749	95-944

^∗Two patients died before confirmed disease evaluations and were excluded from the analysis.